AngioDynamics (NASDAQ:ANGO – Get Free Report) issued an update on its FY 2027 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of -0.290–0.240 for the period, compared to the consensus EPS estimate of -0.190. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $328.7 million.
Analyst Ratings Changes
A number of analysts recently issued reports on ANGO shares. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Canaccord Genuity Group cut their price objective on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.67.
Get Our Latest Research Report on AngioDynamics
AngioDynamics Stock Down 0.2%
AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The company had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts anticipate that AngioDynamics will post -0.23 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in ANGO. Kemnay Advisory Services Inc. bought a new stake in AngioDynamics during the fourth quarter valued at about $27,000. State of Wyoming bought a new position in AngioDynamics in the second quarter worth about $31,000. Russell Investments Group Ltd. raised its holdings in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 4,268 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of AngioDynamics by 106.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier’s stock worth $83,000 after acquiring an additional 3,846 shares in the last quarter. 89.43% of the stock is owned by institutional investors.
About AngioDynamics
AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.
Read More
- Five stocks we like better than AngioDynamics
- CEOs Sell Millions Worth of These 3 Big Name Stocks—What It Means for Investors
- Fission for Profits: Unlocking America’s Uranium Vault
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
